Afecta Pharmaceuticals

Afecta Pharmaceuticals, Inc. is a patient-centered, physician-led pharmaceutical company focused on discovering and optimizing small molecule therapies for inflammatory diseases. The company has validated its proprietary AI-driven disease/drug targeting platform, PharmetRx™, through the discovery and optimization of SPN-810, a drug developed in collaboration with Supernus Pharmaceuticals. SPN-810 has received FDA Fast Track designation and is expected to enter the market in 2019, with peak sales projected to reach $1 billion. Afecta has now developed a new low-risk small molecule immunomodulatory drug.